In: Biology
What is a possible way to introduce a selective inhibitor drug for phosphodiesterase-4 (PDE4) subtypes ?
Phosphodiesterase-4 (PDE4) ia an enzyme mainaly present in immune cells and brain cells. They have a degradative action on the second messenger cyclic adenosine monophosphate (cAMP) and cGMP (cyclic guanosine monophosphate) as well, depending on the subtype. PDE4 inhibitors are drugs that blocks one or more of the five subtypes of the enzyme phosphodiesterase (PDE), thereby preventing the inactivation of the intracellular second messengers. They can suppress a variety of inflammatory cell functions that contribute to their anti-inflammatory actions in immunity, CNS, etc.
PDE4 subtypes include PDE4A, PDE4B , PDE4C ,PDE4D, etc.
The use of selective PDE4 inhibitors can inactivate each of the aforementioned PDE4 subtypes.
Some of the clinically proven and used selective inhibitors to PDE4 are as follows:
Rolipram - targets phosphodiesterase 4B
Cilomilast - targets phosphodiesterase 4D
Crisaborole - targets PDE4C
Piclamilast - targets PDE4A